- Catalent Inc CTLT has reported Q4 sales of $1.19 billion, +25% Y/Y as reported, or 22% in constant currency, edging out analysts' average expectation of $1.14 billion.
- Adjusted EPS of $1.16 surpassed the consensus of $1.03.
- Adjusted EBITDA was $348 million, or a margin of 29.3%, compared to $268 million (28.2%) a year ago.
- Biologics segment sales increased 69% (66% cc) to $603 million.
- Softgel and Oral Technologies segment revenues of $301 million were up 3% (-1% cc).
- The Oral and Specialty Delivery segment's sales were $186 million, a decrease of 15% (-19% cc).
- Clinical Supply Services segment revenues improved 25% (21% cc) to $105 million.
- Guidance: For FY22, Catalent expects revenue of $4.30 billion - $4.50 billion, versus the consensus of $4.33 billion.
- It expects adjusted EBITDA of $1.13 billion - $1.20 billion and adjusted net income of $585 million - $650 million.
- Concurrently, Catalent agreed to acquire Bettera Brands from Highlander Partners for $1 billion.
- Bettera manufacturers gummy, soft chew, and lozenge segments of the nutritional supplements market.
- It maintains four manufacturing operations in California, Virginia, New Jersey, and Indiana.
- The transaction is expected to close by the end of 2021.
- Catalent held cash and cash equivalents of $896 million as of June 30, 2021.
- Related Content: Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts.
- Price Action: CTLT stock is up 0.06% at $129.85 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
